according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Zilpaterol Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Veterinary product

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated exposure, Category 2

H373: May cause damage to organs through pro-

longed or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word : Warning

Hazard statements : H373 May cause damage to organs through prolonged

or repeated exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

Precautionary statements : Prevention:

P260 Do not breathe dust.

Response:

P314 Get medical advice/ attention if you feel unwell.

Hazardous components which must be listed on the label:

Zilpaterol

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Zilpaterol	119520-06-8	Acute Tox. 4; H302 Acute Tox. 4; H332 STOT RE 1; H372 (Cardio-vascular system, Central nervous system, Lungs)	>= 1 - < 10
		Acute toxicity esti- mate	
		Acute oral toxicity: 500 mg/kg	

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

he skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avo

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage

areas and containers

: Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

dusts non-specific 4 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable

dust)

Basis: IE OEL

10 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable

dust)

Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Zilpaterol	119520-06- 8	TWA	1 μg/m3	Internal
		Wipe limit	10 μg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Polyethylene glycol castor oil	Workers	Inhalation	Long-term systemic effects	16.4 mg/m3
	Workers	Skin contact	Long-term systemic effects	4.67 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	2.9 mg/m3
	Consumers	Skin contact	Long-term systemic effects	1.67 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	1.67 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Polyethylene glycol castor oil	Fresh water	0.000 mg/l
	Freshwater - intermittent	0.0661 mg/l
	Marine water	0.000 mg/l
	Marine water - intermittent	0.00661 mg/l
	Fresh water sediment	0.0129 mg/kg dry
		weight (d.w.)
	Marine sediment	0.00129 mg/kg
		dry weight (d.w.)
	Soil	0.00258 mg/kg
		dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version **Revision Date:** SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

Personal protective equipment

Eye/face protection Wear the following personal protective equipment:

Safety goggles

Equipment should conform to I.S. EN 166

Hand protection

Material Chemical-resistant gloves

Remarks Choose gloves to protect hands against chemicals depending

> on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

end of workday.

Skin and body protection

Filter type

Skin should be washed after contact.

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state powder

Colour tan

Odour No data available

Odour Threshold No data available

Melting point/freezing point No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower : No data available

flammability limit

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 3.3
 28.09.2024
 29181-00026
 Date of first issue: 07.11.2014

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Vapour pressure : No data available

Relative density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Components:

Zilpaterol:

Acute oral toxicity : LD50 (Mouse, male and female): 430 - 580 mg/kg

LD50 (Rat, male and female): 890 - 1,325 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Symptoms: Tremors, Breathing difficulties

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Acute toxicity (other routes of :

administration)

TDLo (Rabbit): 9.6 %

Application Route: see user defined free text

Symptoms: Increased pulse rate

Skin corrosion/irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 3.3
 28.09.2024
 29181-00026
 Date of first issue: 07.11.2014

Components:

Zilpaterol:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Zilpaterol:

Species : Rabbit

Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Zilpaterol:

Test Type : Maximisation Test

Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Zilpaterol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster ovary cells

Result: negative

Test Type: Mouse Lymphoma Test system: mouse lymphoma cells

Result: negative

Test Type: unscheduled DNA synthesis assay

Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

Species: Mouse Application Route: Oral Result: negative

Test Type: in vivo assay

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Zilpaterol:

Species : Rat, male and female

Application Route : oral (feed) Exposure time : 104 weeks

0.05 mg/kg body weight0.125 mg/kg body weight

Result : negative Target Organs : Ovary

Species : Mouse
Application Route : Oral
Exposure time : 18 Months

0.02 mg/kg body weight 0.05 mg/kg body weight

Result : negative Target Organs : Blood

Reproductive toxicity

Not classified based on available information.

Components:

Zilpaterol:

Effects on fertility : Test Type: Two-generation study

Species: Rat, male

Application Route: oral (feed)

Fertility: NOAEL: 1.8 mg/kg body weight

Result: No effects on fertility and early embryonic develop-

ment were detected.

Test Type: Two-generation study

Species: Rat, male

Application Route: oral (feed)

Fertility: NOAEL: 0.94 mg/kg body weight

Result: No effects on fertility and early embryonic develop-

ment were detected.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

Effects on foetal develop-

ment

: Test Type: Embryo-foetal development

Species: Rat, female Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight Embryo-foetal toxicity: LOAEL: 50 mg/kg body weight Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high ma-

ternally toxic doses

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Zilpaterol:

Target Organs : Cardio-vascular system, Central nervous system, Lungs
Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Zilpaterol:

Species : Monkey
NOAEL : 0.01 mg/kg
LOAEL : 0.05 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Target Organs : Cardio-vascular system

Symptoms : Increased pulse rate, Lowered blood pressure

Species : Rat, male and female

LOAEL : 0.05 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

Target Organs : Cardio-vascular system Symptoms : Lowered blood pressure

Species : Pig, male and female

NOAEL : 0.05 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Heart

Species : Rat, male and female

NOAEL : 0.250 mg/kg
Application Route : oral (feed)
Exposure time : 52 Weeks

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

Target Organs : Cardio-vascular system

Symptoms : slow pulse

Species : Dog Application Route : Dermal

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Zilpaterol:

Ingestion : Target Organs: Lungs

Symptoms: Tremors, Increased pulse rate Target Organs: Central nervous system

SECTION 12: Ecological information

12.1 Toxicity

Components:

Zilpaterol:

Toxicity to algae/aquatic plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

12.2 Persistence and degradability

Components:

Zilpaterol:

Stability in water Hydrolysis: 0 %(5 d)

12.3 Bioaccumulative potential

Components:

Zilpaterol:

Partition coefficient: n-

octanol/water

: log Pow: 1

12.4 Mobility in soil

Components:

Zilpaterol:

Distribution among environ: log Koc: 2.8

mental compartments

12.5 Results of PBT and vPvB assessment

Product:

: This substance/mixture contains no components considered Assessment

> to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment The substance/mixture does not contain components consid-

> ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone

layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia-

ment and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed. H332 : Harmful if inhaled.

H372 : Causes damage to organs through prolonged or repeated

exposure.

Full text of other abbreviations

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

Acute Tox. : Acute toxicity

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by Road: AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sheet

Sources of key data used to compile the Safety Data

: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

STOT RE 2 H373 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 29181-00026 Date of first issue: 07.11.2014

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN